Evaluation of Humanized CAR T-Cell Therapy ARI0002h Targeting BCMA in Patients with Relapsed/Refractory Multiple Myeloma Resistant to Proteasome Inhibitors, Immunomodulators, and Anti-CD38 Antibody

The primary objective of this clinical trial is to evaluate the efficacy and safety of **humanized CART** directed against **BCMA** (ARI0002h) in patients with **relapsed/refractory multiple myeloma** who have previously been treated with proteasome inhibitors, immunomodulators, and anti-CD38 antibody. This study is clinically relevant as it addresses the need for effective treatment options in patients with multiple myeloma who have exhausted standard therapies, potentially improving outcomes and quality of life for this patient population.

The clinical trial involves participants diagnosed with **Multiple Myeloma**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically includes adults and older adults. The trial does not focus on a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria for the trial population, as well as specific lifestyle considerations such as diet, physical activity, or habits, have not been disclosed. Key inclusion or exclusion criteria are also not specified by the sponsor.

The clinical trial is designed to evaluate the efficacy and safety of a humanized **CART** directed against **BCMA** in patients with relapsed or refractory **Multiple Myeloma** who have previously been treated with proteasome inhibitors, immunomodulators, and anti-CD38 antibodies. This study is a Phase 4 trial, which is typically conducted to monitor the long-term effects of a treatment after it has been approved for public use. The trial follows a randomized, double-blind, controlled design to ensure the reliability and validity of the results. The estimated recruitment start date was June 1, 2020, and the trial is expected to conclude by June 2, 2025, making the overall duration approximately five years.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. This visit will involve a comprehensive assessment of the patient's medical history, current health status, and previous treatments. Following successful inclusion, participants will be randomly assigned to either the treatment group or the control group. Throughout the trial, regular follow-up visits will be scheduled to monitor the participants' response to the treatment, assess any adverse effects, and ensure adherence to the study protocol. These visits are crucial for collecting data on the primary and secondary endpoints of the trial.

The end-of-study visit will mark the conclusion of the participant's involvement in the trial. During this visit, a final evaluation will be conducted to gather data on the long-term effects of the treatment. The expected length of participant involvement will vary depending on individual response to the treatment and adherence to the study protocol. Conditions that may lead to early termination from the study include significant adverse effects, withdrawal of consent, or any other medical reasons deemed necessary by the study investigators. Participants' safety and well-being are prioritized throughout the trial, and all procedures are conducted in accordance with ethical guidelines and regulatory requirements.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a paediatric formulation or if it has orphan drug status. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the study may include non-experimental treatments such as standard-of-care therapy, placebo, or comparator treatment. However, the data does not provide explicit details about these non-experimental treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these treatments is also not available in the provided data.

The clinical trial is in Phase 4, focusing on post-marketing surveillance to assess the efficacy of the intervention. The trial is scheduled to run from June 1, 2020, to June 2, 2025. Efficacy will be evaluated through specific parameters or endpoints, although these are not detailed in the provided data. The trial will likely involve systematic collection and analysis of data at predetermined timepoints throughout the study duration. The methods for measuring and analyzing efficacy parameters are not specified, but typically include validated scales, laboratory tests, or patient-reported outcomes. The trial's design and execution will adhere to rigorous standards to ensure the reliability and validity of the efficacy assessments.